ClinicalTrials.gg
CompletedNCT03272347Updated Mar 29, 2023Results posted

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

A Phase 2 interventional study of Islatravir and Placebo to Islatravir in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has -1 infection
  • Is naïve to anti-retroviral therapy (ART).
  • Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
  • Female is not pregnant, not breastfeeding, not a woman of (WOCBP); but if WOCBP agrees to follow the guidance
  • All participants, male and female, agree to use barrier methods of contraception when engaged in any sexual activity during treatment and for 6 weeks following treatment.

Exclusion criteria

Exclusion Criteria:

  • Is a user of recreational or illicit drugs or has had a history of drug or alcohol abuse or dependence that may interfere with trial participation
  • Has significant or other to any of the components of the study drugs
  • Has a history of ≤5 years prior
  • Female expects to donate eggs at any time during the study
  • Is breastfeeding or expecting to conceive
  • A who has a positive urine pregnancy test on Day 1 before the first dose of study treatment
  • Has been treated for a viral infection other than -1, such as , with an agent that is active against HIV-1
  • Has used systemic therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study
  • Requires any of the following prohibited medications: Carbamazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Herbal remedies, St. John's Wort, Modafinil, Bosentan, Nafcillin, Pentostatin
  • Is currently participating in or has participated in an interventional clinical trial with an compound or device within 30 days of signing to participate in this current trial
  • Has a documented or known virologic resistance to any approved HIV-1 reverse transcriptase inhibitor, protease inhibitor, integrase inhibitor
  • Has active virus (HCV) coinfection defined as detectable HCV RNA or HBV co-infection defined as hepatitis B surface antigen [HBsAg]-positive
  • Has a current (active) diagnosis of acute hepatitis due to any cause
  • Has previously been randomized in a study and received islatravir (MK-8591), DOR, Doravirine, Tenofovir, Lamivudine, or 3TC.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Islatravir 0.25 mg

    Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.

    Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir

  • Experimental
    Islatravir 0.75 mg

    Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.

    Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir

  • Experimental
    Islatravir 2.25 mg

    Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.

    Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir

  • Active comparator
    DOR/3TC/TDF

    Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and a fixed dose combination of DOR/3TC/TDF consisting of 100 mg DOR + 300 mg 3TC + 300 mg TDF for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only DOR/3TC/TDF QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.

    Drug: Placebo to Islatravir · Drug: Placebo to Doravirine · Drug: Placebo to Lamivudine · Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir

Interventions

  • Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.

    Also known as: MK-8591

  • DrugPlacebo to Islatravir

    Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks

  • Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks

    Also known as: MK-1439

  • DrugPlacebo to Doravirine

    Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks

  • Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks

    Also known as: 3TC

  • DrugPlacebo to Lamivudine

    Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks

  • DrugDoravirine/Lamivudine/Tenofovir Disoproxil Fumarate

    Drug page: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

    Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.

    Also known as: MK-1439A

  • DrugPlacebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

    Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks

  • DrugDoravirine/Islatravir

    Drug pages: Doravirine · Islatravir

    Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks

    Also known as: MK-8591A

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24

    Blood samples were collected and plasma human immunodeficiency virus 1 (HIV-1) ribonucleic acid (RNA) were quantified using a real time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.

    Time frame: Week 24

  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

    Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.

    Time frame: Week 48

  3. Number of Participants Experiencing Adverse Events (AEs) up to Week 144

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: Up to 144 weeks

  4. Number of Participants Discontinuing Study Drug Due to AEs up to Week 144

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: Up to 144 weeks

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

    Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

    Time frame: Up to 24 weeks after 3TC and Placebo are discontinued from the regimen (up to approximately 60 weeks after initiating treatment)

  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen

    Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

    Time frame: Up to 48 weeks

  3. Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)

    Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure. The percentage of participants with HIV-1 RNA \<50 copies in Part 4 are reported.

    Time frame: Up to Week 192

  4. Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24

    Blood samples were collected and cluster of differentiation (CD4)+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

    Time frame: Baseline and Week 24

  5. Change From Baseline in CD4+ T-cell Count at Week 48

    Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

    Time frame: Baseline and Week 48

  6. Change From Baseline in CD4+ T-cell Count at Week 96

    Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

    Time frame: Baseline and Week 96

  7. Change From Baseline in CD4+ T-cell Count at Week 144

    Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

    Time frame: Baseline and Week 144

  8. Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4)

    Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Week 144 value. The change from baseline in CD4+ T-cell count at Week 192 (Part 4) are reported.

    Time frame: Baseline and Week 192

  9. Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

    Time frame: Up to 24 weeks

  10. Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

    Time frame: Up to 24 weeks

  11. Number of Participants Experiencing AEs From Week 96 Through Study Duration

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: Week 96 up to Week 192

  12. Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: Week 96 up to Week 192

  13. Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced AEs during Part 4 are reported.

    Time frame: Week 144 up to Week 192

  14. Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued the study drug due to AEs in Part 4 are reported.

    Time frame: Week 144 up to Week 192

07

Results

Posted Apr 27, 2022

Participant flow

Treatment-naïve participants ≥18 years of age with human immunodeficiency virus type 1 (HIV-1) were enrolled in this study.

Participant flow — Overall Study
MilestoneIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Started31303131
Treated29303131
Completed20241924
Not completed116127
Withdrew: Death0001
Withdrew: Lost to follow-up1351
Withdrew: Physician decision4254
Withdrew: Screen failure1000
Withdrew: Withdrawal by subject5121

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24

Blood samples were collected and plasma human immunodeficiency virus 1 (HIV-1) ribonucleic acid (RNA) were quantified using a real time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24
Percentage of participantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 2493.1100.090.390.3
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: 2.9 · 95% CI -12.5 to 18.3Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: 9.6 · 95% CI -3.8 to 23.0Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: 0.2 · 95% CI -16.0 to 16.3Islatravir minus DOR/3TC/TDF
PrimaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Percentage of participantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 4889.790.077.483.9
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: 6.1 · 95% CI -12.2 to 24.4Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: 6.2 · 95% CI -12.2 to 24.6Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -6.1 · 95% CI -27.1 to 14.8Islatravir minus DOR/3TC/TDF
PrimaryNumber of Participants Experiencing Adverse Events (AEs) up to Week 144

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) up to Week 144
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Number of Participants Experiencing Adverse Events (AEs) up to Week 14426272427
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Difference in %: 2.6 · 95% CI -15.7 to 20.5Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Difference in %: 2.9 · 95% CI -15.0 to 20.8Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Difference in %: -9.7 · 95% CI -29.4 to 10.1Islatravir minus DOR/3TC/TDF
PrimaryNumber of Participants Discontinuing Study Drug Due to AEs up to Week 144

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
Up to 144 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs up to Week 144
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Number of Participants Discontinuing Study Drug Due to AEs up to Week 1441021
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Difference in %: 0.2 · 95% CI -13.4 to 14.5Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Difference in %: -3.2 · 95% CI -16.4 to 8.5Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Difference in %: 3.2 · 95% CI -10.8 to 18.1Islatravir minus DOR/3TC/TDF
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

Time frame:
Up to 24 weeks after 3TC and Placebo are discontinued from the regimen (up to approximately 60 weeks after initiating treatment)
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
Percentage of participantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen86.290.088.996.4
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: -9.7 · 95% CI -26.1 to 6.6Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: -6.2 · 95% CI -21.5 to 9.1Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -7.5 · 95% CI -23.9 to 8.8Islatravir minus DOR/3TC/TDF
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen

Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

Time frame:
Up to 48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen
Percentage of participantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen62.156.759.360.7
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: 2.2 · 95% CI -23.4 to 27.7Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: -3.7 · 95% CI -29.6 to 22.1Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -1.3 · 95% CI -27.7 to 25.2Islatravir minus DOR/3TC/TDF
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)

Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure. The percentage of participants with HIV-1 RNA \<50 copies in Part 4 are reported.

Time frame:
Up to Week 192
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)
Percentage of participantsDOR/ISL Continued (Part 4)DOR/ISL Switch (Part 4)
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)85.195.5
SecondaryChange From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24

Blood samples were collected and cluster of differentiation (CD4)+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

Time frame:
Baseline and Week 24
Reported as:
Mean · cells/mm^3
Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24
cells/mm^3Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24220.5 (170.3 to 270.8)192.8 (117.9 to 267.7)142.9 (89.9 to 196.0)142.1 (105.7 to 178.5)
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: 78.4 · 95% CI 18.8 to 138.1Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: 50.7 · 95% CI -31.7 to 133.1Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: 0.8 · 95% CI -63.0 to 64.7Islatravir minus DOR/3TC/TDF
SecondaryChange From Baseline in CD4+ T-cell Count at Week 48

Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

Time frame:
Baseline and Week 48
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4+ T-cell Count at Week 48
cells/mm^3Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Change From Baseline in CD4+ T-cell Count at Week 48182.0 (119.6 to 244.5)183.0 (124.7 to 241.2)100.7 (25.0 to 176.3)181.4 (137.2 to 225.6)
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: 0.6 · 95% CI -74.1 to 75.3Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: 1.5 · 95% CI -70.7 to 73.8Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -80.8 · 95% CI -165.6 to 4.0Islatravir minus DOR/3TC/TDF
SecondaryChange From Baseline in CD4+ T-cell Count at Week 96

Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

Time frame:
Baseline and Week 96
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4+ T-cell Count at Week 96
cells/mm^3Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Change From Baseline in CD4+ T-cell Count at Week 96243.4 (165.5 to 321.3)161.3 (90.2 to 232.4)136.5 (57.0 to 216.0)268.9 (188.5 to 349.3)
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: -25.5 · 95% CI -134.8 to 83.8Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: -107.6 · 95% CI -212.1 to -3.1Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -132.4 · 95% CI -242.9 to -21.9Islatravir minus DOR/3TC/TDF
SecondaryChange From Baseline in CD4+ T-cell Count at Week 144

Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.

Time frame:
Baseline and Week 144
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4+ T-cell Count at Week 144
cells/mm^3Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Change From Baseline in CD4+ T-cell Count at Week 144204.4 (102.0 to 306.7)209.0 (111.5 to 306.6)162.9 (70.2 to 255.5)270.0 (183.2 to 356.8)
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Treatment difference: -65.6 · 95% CI -195.3 to 64.0Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Treatment difference: -61.0 · 95% CI -188.7 to 66.8Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Treatment difference: -107.1 · 95% CI -231.2 to 16.9Islatravir minus DOR/3TC/TDF
SecondaryChange From Baseline in CD4+ T-cell Count at Week 192 (Part 4)

Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Week 144 value. The change from baseline in CD4+ T-cell count at Week 192 (Part 4) are reported.

Time frame:
Baseline and Week 192
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4)
cells/mm^3DOR/ISL Continued (Part 4)DOR/ISL Switch (Part 4)
Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4)3.8 (-1.9 to 9.5)-3.4 (-12.0 to 5.2)
SecondaryNumber of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen18201416
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Difference in %: 4.9 · 95% CI -20.3 to 29.6Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Difference in %: 9.5 · 95% CI -15.4 to 33.5Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Difference in %: -5.3 · 95% CI -30.6 to 20.7Islatravir minus DOR/3TC/TDF
SecondaryNumber of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDF
Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen0021
Statistical analysis
  • Islatravir 0.25 mg vs DOR/3TC/TDF · Difference in %: -3.6 · 95% CI -17.9 to 8.5Islatravir minus DOR/3TC/TDF
  • Islatravir 0.75 mg vs DOR/3TC/TDF · Difference in %: -3.6 · 95% CI -17.9 to 8.2Islatravir minus DOR/3TC/TDF
  • Islatravir 2.25 mg vs DOR/3TC/TDF · Difference in %: 3.8 · 95% CI -11.5 to 20.6Islatravir minus DOR/3TC/TDF
SecondaryNumber of Participants Experiencing AEs From Week 96 Through Study Duration

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
Week 96 up to Week 192
Reported as:
Count of participants · Participants
Number of Participants Experiencing AEs From Week 96 Through Study Duration
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFDOR/ISL ContinuedDOR/ISL Switch
Number of Participants Experiencing AEs From Week 96 Through Study Duration121911123614
SecondaryNumber of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
Week 96 up to Week 192
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration
ParticipantsIslatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFDOR/ISL ContinuedDOR/ISL Switch
Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration100000
SecondaryNumber of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced AEs during Part 4 are reported.

Time frame:
Week 144 up to Week 192
Reported as:
Count of participants · Participants
Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
ParticipantsDOR/ISL Continued (Part 4)DOR/ISL Switch (Part 4)
Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)3614
SecondaryNumber of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued the study drug due to AEs in Part 4 are reported.

Time frame:
Week 144 up to Week 192
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
ParticipantsDOR/ISL Continued (Part 4)DOR/ISL Switch (Part 4)
Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)00

Adverse events

Collected over For All-Cause Mortality: from randomization up to 198 weeks. For AEs: from first treatment up to 198 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Islatravir 0.25mg0/31 (0%)2/29 (6.9%)22/29 (75.9%)
Islatravir 0.75mg0/30 (0%)6/30 (20%)26/30 (86.7%)
Islatravir 2.25mg0/31 (0%)2/31 (6.5%)23/31 (74.2%)
DOR/3TC/TDF1/31 (3.2%)4/31 (12.9%)22/31 (71%)
DOR/ISL Continued0/67 (0%)2/67 (3%)21/67 (31.3%)
DOR/ISL Switch0/22 (0%)1/22 (4.5%)11/22 (50%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventIslatravir 0.25mgIslatravir 0.75mgIslatravir 2.25mgDOR/3TC/TDFDOR/ISL ContinuedDOR/ISL Switch
Suicide attemptPsychiatric disorders0/292/300/310/310/670/22
COVID-19Infections and infestations0/290/300/310/310/671/22
Atrial fibrillationCardiac disorders1/290/300/310/310/670/22
Burkitt's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/290/300/310/310/670/22
LymphadenopathyBlood and lymphatic system disorders0/291/300/310/310/670/22
AppendicitisInfections and infestations0/291/300/310/311/670/22
Large intestine infectionInfections and infestations0/291/301/310/310/670/22
Ankle fractureInjury, poisoning and procedural complications0/291/300/310/310/670/22
Facial paralysisNervous system disorders0/291/300/310/310/670/22
Alcohol withdrawal syndromePsychiatric disorders0/291/300/310/310/670/22
Most frequent other events
Showing 10 of 73
Most frequent other events
EventIslatravir 0.25mgIslatravir 0.75mgIslatravir 2.25mgDOR/3TC/TDFDOR/ISL ContinuedDOR/ISL Switch
NasopharyngitisInfections and infestations2/299/302/317/310/671/22
SyphilisInfections and infestations6/298/302/316/314/671/22
DiarrhoeaGastrointestinal disorders1/296/303/318/310/673/22
BronchitisInfections and infestations2/297/301/315/310/670/22
COVID-19Infections and infestations0/293/301/311/312/675/22
Vitamin D deficiencyMetabolism and nutrition disorders1/296/304/312/310/670/22
AnxietyPsychiatric disorders3/296/300/311/310/672/22
HeadacheNervous system disorders5/292/305/314/310/670/22
NauseaGastrointestinal disorders1/295/303/313/310/670/22
SinusitisInfections and infestations4/290/300/311/310/671/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Mean32.3 ± 13.330.0 ± 9.032.4 ± 11.829.4 ± 8.931.0 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Female133310
Male30272828113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Hispanic or Latino1419121560
Not Hispanic or Latino1611181560
Unknown or Not Reported10113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American668525
White2424212493
More than one race00202
Unknown or Not Reported10012
CD4+ T-Cell Count
CD4+ T-Cell Count(cells/mm^3)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Mean450.8 ± 170.0538.5 ± 165.5469.6 ± 203.3508.5 ± 206.8492.1 ± 188.5
Participants with <=100,000 copies/mL of HIV-1 RNA
Participants with <=100,000 copies/mL of HIV-1 RNA(Participants)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Count of participants2423232494
Participants with >100,000 copies/mL of HIV-1 RNA
Participants with >100,000 copies/mL of HIV-1 RNA(Participants)Islatravir 0.25 mgIslatravir 0.75 mgIslatravir 2.25 mgDOR/3TC/TDFTotal
Count of participants778729
08

Study locations

26 sites
  • Pueblo Family Physicians ( Site 0119)
    Phoenix, Arizona 85015, United States
  • University California / Davis ( Site 0101)
    Sacramento, California 95817, United States
  • Whitman Walker Clinic ( Site 0108)
    Washington, District of Columbia 20005, United States
  • Orlando Immunology Center (OIC) ( Site 0105)
    Orlando, Florida 32803, United States
  • Northstar Medical Center ( Site 0102)
    Chicago, Illinois 60657, United States
  • Kansas City CARE Clinic ( Site 0106)
    Kansas City, Missouri 64111, United States
  • Saint Hope Foundation, Inc. ( Site 0116)
    Bellaire, Texas 77401, United States
  • North Texas Infectious Diseases Consultants, PA ( Site 0103)
    Dallas, Texas 75246, United States
  • Tarrant County Infectious Disease Associates ( Site 0112)
    Fort Worth, Texas 76104, United States
  • The Crofoot Research Center, Inc. ( Site 0118)
    Houston, Texas 77098, United States
  • Clinica Arauco Salud ( Site 0200)
    Santiago, RM, Chile
  • Biomedica Research Group ( Site 0202)
    Santiago, Chile
  • Hospital Dr. Hernan Henriquez Aravena ( Site 0203)
    Temuco, Chile
  • Hopital Avicenne ( Site 2302)
    Bobigny, France
  • Hopital Saint-Andre ( Site 2307)
    Bordeaux, France
  • CHU Hotel Dieu ( Site 2308)
    Nantes, France
  • CHU de Nice Hopital Archet 1 ( Site 2303)
    Nice, France
  • Hopital Bichat - Claude Bernard ( Site 2309)
    Paris, France
  • Hopital Pitie Salpetriere ( Site 2305)
    Paris, France
  • Hopital Saint Louis ( Site 2306)
    Paris, France
  • Centre Hospitalier de Tourcoing ( Site 2301)
    Tourcoing, France
  • Brighton and Sussex University Hospitals NHS Trust ( Site 2105)
    Brighton, East Sussex, United Kingdom
  • Chelsea and Westminster Hospital ( Site 2101)
    London, United Kingdom
  • Royal London Hospital ( Site 2103)
    London, United Kingdom
  • The Royal Free London NHS Foundation Trust ( Site 2102)
    London, United Kingdom
  • North Manchester General Hospital ( Site 2104)
    Manchester, United Kingdom
09

References and documents

Publications

  • Molina JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, Klopfer SO, Grandhi A, Eves K, Hepler D, Robertson MN, Hwang C, Hanna GJ, Correll T. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine. J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):68-72. doi: 10.1097/QAI.0000000000002879. Epub 2021 Dec 8. PubMed 35972855 ↗
  • Molina JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, DeJesus E, Olsen Klopfer S, Grandhi A, Eves K, Robertson MN, Correll T, Hwang C, Hanna GJ, Sklar P. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV. 2021 Jun;8(6):e324-e333. doi: 10.1016/S2352-3018(21)00021-7. Epub 2021 May 14. PubMed 34000227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2021, 39 months.

Results were first posted in Apr 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 5, 2017
StartActual
Nov 27, 2017
Primary completionActual
Mar 8, 2021
CompletionActual
Mar 9, 2022
Results first posted
Apr 27, 2022
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03272347
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Nov 27, 2017
Primary completion
Mar 8, 2021
Completion
Mar 9, 2022
Results posted
Apr 27, 2022
Last update
Mar 29, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Islatravir · Doravirine · Lamivudine · Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

Start the discussion